查詢結果分析
來源資料
相關文獻
- Lansoprazole三合療法與Bismuth三合療法對國人幽門曲狀桿菌陽性消化性潰瘍療效之比較
- 一週四合療法對治療國人幽門曲狀桿菌感染之療效
- Campylobacter Pylori, Gastritis and Peptic Ulceration
- A Study of Campylobacter Pylori in Peptic Ulcer Disease
- Impact of Helicobacter Pylori Eradication on the Development of MALT, Gland Atrophy and Intestinal Metaplasia of the Antrum
- Helicobacter Pylori Infection in Patients with Chronic Renal Failure
- Helicobacter Pylori Infection and Risk of Peptic Ulcer Among Cirrhotic Patients
- 如何診斷幽門曲狀桿菌感染
- Gastric Emptying Half-time in Patients with Helicobacter Pylori Associated Gastritis or Gastric Ulcer Diseases
- 上胃腸道最常見的感染病菌之一--幽門曲狀桿菌
頁籤選單縮合
題 名 | Lansoprazole三合療法與Bismuth三合療法對國人幽門曲狀桿菌陽性消化性潰瘍療效之比較=The Effect of Lansoprazole-based Triple Therapy and Bismuth-based Triple Therapy on the Eradication of Helicobacter Pylori in Chinese |
---|---|
作 者 | 羅清池; 許秉毅; 羅錦河; 黎國洪; 鄭錦翔; 陳海雄; 徐瑞宏; 陳泰安; 古明崑; 曾暉華; 彭南靖; 賈愛華; 陳文旭; | 書刊名 | 內科學誌 |
卷 期 | 10:2 1999.04[民88.04] |
頁 次 | 頁71-76 |
分類號 | 415.5 |
關鍵詞 | 幽門曲狀桿菌; 根除治療; Lansoprazole三合療法; Bismuth三合療法; Helicobacter pylori; Eradication therapy; Lansoprazole triple therapy; Bismuth triple therapy; |
語 文 | 中文(Chinese) |
中文摘要 | 自民國87年3月至9月間,我們進行一項前瞻性之研究,比較以lansoprazole 為基礎之三合療法與傳統的bismuth三合療法,對於國人幽門曲狀桿菌的除菌效果、潰瘍癒 合率、副作用比率、以及費用之高低。在研究期間,共有53位幽門曲狀桿菌陽性之消化性 潰瘍患者,隨機分成二組:第一組(N=26)接受lansoprazole為基礎之三合療法(lansoprazole 30mg一天二次,amoxicillin 500mg一天四次,及clarithromycin 500mg一天二次共一週, 而後給予ranitidine 150mg一天二次共7週);第二組(N=27)則接受傳統bismuth三合療法 (colloidal bismuth subcitrate 120mg一天四次,metronidazole 250mg一天四次,及 tetracycline 500mg一天四次共二週,而後給予ranitidine 150mg一天二次共6週)。在 治療8週後,以胃鏡追蹤潰瘍癒合情形,以及幽門曲狀桿菌是否被根除。結果:第一組共有 25人完成追蹤與治療,第二組共有26人完成追蹤,25人完成治療,對幽門曲狀桿菌的除菌 率,二組並無差異(per protoco1:76%vs72%,intention to treat:76%vs69%,P>0.05),潰 瘍癒合率亦無差異(per protocol:88%vs84%,intention to treat:88%vs85%,P>0.05);藥 物遵從性方面亦無差異(0%vs3.7%);但在副作用發生率方面lansoprazole組較bismuth組為 低,分別為8%及50%(P<0.05);而在8週之治療費用方面:lansoprazole組為4596元,而 bismuth組則為3169元,二組有顯著之差異。結論:本研究顯示:(1)以lansoprazole為基 礎之新三合療法與傳統bismuth三合療法治療國人幽門曲狀桿菌陽性之消化性潰瘍,在除菌 率及潰瘍癒合率上,二組並無差異;(2)在副作用發生率方面,以lansoprazole為基礎之新 三合療法較低但其花費較高。 情A以lansoprazole為基礎之新三合療法較低,但其花費較高。 |
英文摘要 | From March to September 1998, we conducted a prospective study to investigate the effect of lansoprazole-based triple therapy and bismuth-based triple therapy on eradication of Helicobacter pylon and healing of peptic ulcers. During the study period, 53 patients with H. pylon related ulcers were enrolled and randomized divided into 2 groups. Group 1 (N=26) received a 1-week lansoprazole-based triple therapy ( lansoprazole 30 mg bid, amoxicillin 500 mg qid and clarithromycin 500 mg bid ) and then 7-week H2-blocker ( ranitidine 150 mg bid) therapy. Group 2 (N=27) received 2-week bismuth-based triple therapy (colloidal bismuth subcitrate 120 mg qid, metronidazole 250 mg qid and tetracycline 500 mg qid ) and then 6-week H2-blocker ( ranitidine 150 mg bid) therapy. Endoscopy was repeated at the end of the 8th week to follow up the gastrointestinal lesions and determine the status of H. pylori. In lansoprazole-based triple therapy group, H. pylori was successfully eradicated in 19 of 25 patients (76%) and ulcer healing was achieved in 22 of 25 patients (88%) by an intention-to-treat analysis. In bismuth-based triple therapy group, H. pylon was successfully eradicated in 18 of 26 patients (69%) and ulcer healing was achieved in 22 of 26 patients (85%) by an intention-to-treat analysis. The incidence of side effects is 8% in lansoprazole-based triple therapy group and 50% in bismuth-based triple therapy group. The cost of 8-week treatment is 4596 NT dollars in lansoprazole-based triple therapy group and 3169 NT dollars in bismuth-based triple therapy group. So we conclude that: (1) There are no significant differences in eradication rate and ulcer healing rate between lansoprazole-based and bismuth-based triple therapy. (2) The incidence of side effects in lansoprazole-based triple therapy group is much lower than that in bismuth-based triple therapy group but the cost of the former is higher than that of the latter. Therefore, both lansoprazole-based triple therapy and bismuth-based triple therapy are not ideal regimen for eradication of H. pylori in Chinese. |
本系統中英文摘要資訊取自各篇刊載內容。